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ABSTRACT: 
 
Introduction: Cardiovascular disease (CVD) is an important cause of mortality and morbidity 
worldwide. CVD morbidity and mortality are associated with significant financial costs related 
to hospitalization, medication, and lost productivity. The concept of the ‘polypill’ for the 
reduction of cardiovascular risk was proposed in 2000. A polypill is a fixed combination of drugs 
in a single tablet or capsule. The initial polypill consisted of three different classes of 
antihypertensive drugs (each at half dose), in addition to aspirin, a statin, and folic acid. The 
challenge today is to produce polypills containing drugs with established efficacy and 
complementary actions.  
Areas covered: The authors provide their expert perspectives on the polypill and consider the 
randomized clinical trials that have evaluated the safety, efficacy, adherence and 
cost-effectiveness of polypills. 
Expert opinion: The polypill makes prescribing easier by reducing the need for complex 
treatment algorithms and dose titration. It also appears to be cost-effective. However, there are 
several issues that need to be addressed before the polypill can be used routinely. A single 
polypill formulation may not be suitable for all patients. It may be necessary to develop several 
types of polypill to meet the needs of different patient groups. 
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1. 1. Introduction 
Cardiovascular disease (CVD) is an important cause of mortality and morbidity 
worldwide. According to estimates, 25 million people in total will die of CVD by 2030 [1]. 
Although CVD mortality rate has declined in high-income countries, it has continued to rise in 
low- and middle-income countries. The rate of premature deaths from CVD ranges from 4% in 
high-income countries to 42% in low-income countries [2,3]. CVD morbidity and mortality are 
associated with significant financial costs related to hospitalization, medication, and lost 
productivity. This CVD epidemic is linked to increased prevalence of well-established, 
modifiable risk factors such as hypertension, diabetes, obesity, dyslipidemia, physical inactivity, 
poor diet, and tobacco use [3]. Large epidemiological studies have demonstrated that the 
aforementioned risk factors account for as  much as 90% of CVD events [4]. 
 
1. 2. Areas covered 
1. 2.1. The concept of the polypill  
The concept of the ‘polypill’ for the reduction of cardiovascular risk was proposed by 
Wald and Law [5] in 2000. A polypill is a fixed combination of drugs in a single tablet or 
capsule. The initial polypill consisted of three different classes of antihypertensive drugs (each at 
half dose), in addition to aspirin, a statin, and folic acid. The challenge today is to produce 
polypills containing drugs with complementary actions and established efficacy in the reduction 
of modifiable risk factors for CVD [3]. 
According to estimates made by Wald and Law, the polypill reduces ischemic heart 
disease (IHD) events by 88% and strokes by 80% compared with placebo. Moreover, they 
suggested that it could be used without needing to consider concomitant risk factors. The polypill 
was developed in order to enhance accessibility, effectiveness of medicines and to improve 
patient adherence. This would be expected to improve cost-effectiveness [6]. Numerous 
randomized controlled trials (RCTs) have evaluated the safety, efficacy, adherence and 
cost-effectiveness of polypills. 
The selection of the constituent drugs to be included in a polypill is a complicated matter. 
Clinical evidence relating to the efficacy of the treatments for known modifiable CVD risk 
factors and the prevalence of adverse events should be considered [3]. The doses of drugs in 
polypills are selected in order to achieve the optimal balance between efficacy and safety [6]. 
Wald and Law performed a meta-analysis to calculate the relative risk reduction associated with 
each individual component of the polypill [7]. Their formulation contained off-patent medicines 
in order to reduce cost. These drugs were used at modest doses to reduce the prevalence of 
adverse effects (AEs). The polypill proposed by Wald and Law can be used in both primary and 
secondary prevention of CVD and contains low-dose aspirin (50 to 125 mg/d), folic acid 0.8 
mg/d, a potent statin (e.g., atorvastatin 10 mg or simvastatin 40 to 80 mg), and three blood 
pressure (BP)-lowering drugs at half the standard dose (chosen from thiazide diuretics, 
beta-blockers, angiotensin converting enzyme [ACE] inhibitors, angiotensin receptor blockers 
[ARBs], and calcium channel blockers) [7]. However, the results of clinical studies have changed 
attitudes towards some of the drugs initially suggested for inclusion in polypills. For example, 
large randomized controlled trials have shown no benefit of folic acid in preventing CVD [8]. 
Low-dose aspirin has been shown to be beneficial only in secondary prevention [9]. In the 
ASPREE trial in the healthy elderly, primary prevention with aspirin (100mg daily) led to a 
significantly increased risk of  bleeding, without reduced risk of CVD [10]. The ARRIVE RCT 
showed no benefit of aspirin (100mg daily) in the primary prevention CVD  in 12,000 
non-diabetic adults with multiple risk factors for CVD [11]. In the ASCEND trial of aspirin 
(100mg daily) for the primary prevention of CVD in participants with diabetes, aspirin reduced 
the risk of vascular events, but this benefit was negated by the increased bleeding hazard [12]. 
Interestingly, it has recently been demonstrated that low dose aspirin (<100mg/day) may only be 
effective in the primary prevention of aspirin in patients weighing <70mg, and that tailoring 
aspirin dose by body weight may be necessary [13]. Whilst this approach has the potential to 
improve the efficacy of aspirin in primary prevention, tailored dosing would be hard to a achieve 
in  a polypill. The evidence supporting other polypill components has increased. Recent studies 
have confirmed the importance of statins, demonstrating that each 1-mmol/L reduction in 
LDL-cholesterol over 5 years is associated with a 11% relative risk reduction in total mortality, 
26% in major ischemic heart disease (IHD) events and 16% in strokes [14]. Statin treatment may 
occasionally result in myopathy, rhabdomyolysis and persistent elevation in transaminases [15]. 
It is also associated with a slightly elevated risk of developing diabetes mellitus [16]. In a 
meta-analysis conducted by Wald and Law, the use of lovastatin (40 mg), simvastatin (40 mg), 
or atorvastatin 10 mg was associated with absolute reduction in low-density lipoprotein (LDL) 
cholesterol by 37%. From this, the authors predicted a 52% relative risk reduction in ischemic 
heart disease and a 17% relative risk reduction in stroke [3,17]. Wald and Law assumed that the 
combination of three different antihypertensive agents used at half of the standard doses would 
safely reduce BP, resulting in a reduction in the prevalence of strokes by 63% and IHD by 46% 
[18]. The goal of combining several drugs at low doses was to minimize the side effects 
observed at high doses, whilst maintaining efficacy. Moreover, the combination of drugs could 
help counterbalance their side effects, e.g. the inclusion of renin-angiotensin system blockers in 
the polypill could help to avoid the hypokalemia and hyperglycemia which might be expected 
from the concurrent administration of diuretics [7]. On the basis of the analysis of RCTs Wald 
and Law suggested that using three antihypertensive drugs in combination and at low doses 
would reduce diastolic blood pressure (DBP) by 11 mmHg and reduce the risk for ischemic heart 
disease by 46% and stroke by 63%. Wald and Law suggested that the formulation should contain 
6 different compounds in order to maximize potential benefits. 
The formulation and manufacturing of a tablet or capsule containing so many active 
compounds presents several challenges. Problems accumulate as the number of active 
ingredients increases. Each additional drug increases the possibility for more AEs. Therefore, 
using too many components could limit the potential patient population [3]. Wald and Law 
estimated that the rate of adverse effects of the polypill would range between 8% and 15% [5]. 
However, the actual rates of adverse effects of long-term treatment with a polypill are not 
known. Formulation of polypills is made more challenging by the range of different chemical 
and physical characteristics of the components. For example, it can be difficult to combine 
compounds with differing solubility and sensitivity to heat and moisture. The range of doses (e.g. 
ramipril at 2.5 mg and atenolol at 100 mg) can also prove challenging. The potential for 
drug-drug interactions and the bioavailability of components should also be considered in the 
preparation of a polypill. Bioavailability, and the achievement of appropriate plasma drug 
concentrations can pose a real difficulty. Patel et al. [19] demonstrated that simvastatin efficacy 
was significantly lower when simvastatin was taken as a part of the Polycap pill (simvastatin 20 
mg, aspirin 100 mg, hydrochlorothiazide [HCTZ] 12.5 mg, atenolol 50 mg, ramipril 5 mg) than 
when it was taken alone. However, surprisingly, the bioavailability of the active metabolite of 
simvastatin was demonstrated to be higher when taken in the combination formulation. Table 1 
summarizes currently available polypills. 
 
Table 1. The summary of currently available polypills working on several risk factors/conditions both for 
primary and secondary preventions.  
 
Product Company Composition Indication Country 
Polycap Cadila Pharma Aspirin (100 mg), atenolol (50 mg), 
thiazide (12.5 mg), ramipril (5 mg) 
and simvastatin (20 mg) 
Primary 
prevention 
India, Zambia 
Trinomia/Sincronium/
Iltria 
Ferrer Aspirin (100 mg), ramipril (2.5 mg; 
5 mg; 10 mg) and either simvastatin 
(40 mg) or atorvastatin (20 mg) 
Secondary 
prevention 
Austria, Belgium, Bulgaria, 
Czech rep. Germany, 
Finland, France, Greece, 
Ireland, Italy, Poland, 
Portugal, Romania, Spain, 
Sweden 
Guatemala, Honduras, 
Dominican Republic, El 
Salvador, Nicaragua, 
Argentina, Chile, Paraguay, 
Ecuador, Mexico 
Zycad-4 ZydusCardiva Aspirin (75 mg), atorvastatin 
(10 mg), ramipril (5 mg) and 
metoprolol (50 mg) which is 
supplied as separate pill 
Secondary 
prevention 
India 
Polytorva USV Aspirin (75 mg), atovastatin (5 mg) 
and ramipril (10 mg) 
Secondary 
prevention 
India 
Ramitorva ZydusCardiva Aspirin (75 mg), atovastatin 
(10 mg) and ramipril (5 mg) 
Secondary 
prevention 
India 
Polypill Cipla, India Amlodipine (2.5 mg), losartan 
(25 mg), hydrochlorothiazide 
Primary 
prevention 
No market approval 
(12.5 mg) and simvastatin (40 mg) 
Red Heart Pill 1™ Dr Reddy’s 
Laboratories 
Aspirin (75 mg), lisinopril (10 mg), 
simvastatin (20 mg) and atenolol 
(50 mg)  
Secondary 
prevention 
No market approval 
Red Heart Pill 2™ Dr Reddy’s 
Laboratories 
Aspirin (75 mg), lisinopril (10 mg), 
simvastatin (20, 40 mg) and 
hydrochlorothiazide (12.5 mg) 
Secondary 
prevention 
No market approval 
PolyIran Alborz Darou 
(Iran) 
Aspirin (81 mg), atorvastatin (20 
mg), enalapril (5 mg) or valsartan 
(40 mg) and hydrochlorothiazide 
(12.5 mg) 
Primary/ 
secondary 
prevention 
No market approval 
 
1. 2.2. Use of the Polypill in primary prevention 
Primary prevention should encompass multiple strategies, including: health policy and 
environmental changes, individual behavioral changes, and the use of drugs with proven efficacy 
and safety [7]. Behavioral interventions aiming at the alteration of individual lifestyles are costly, 
exert only modest and unsustainable impact, and have failed to reduce the occurrence of CVD 
events in large trials [7,20]. Changes in health policy, the environment, and cultural attitudes 
exert a greater impact. However, such interventions are not implemented in most developed and 
developing countries. Primary prevention can be approached at both individual and population 
levels [7]. In the individual approach, screening is used to identify high-risk individuals to enable 
effective risk-management. Such “tailoring” of an intervention to each individual is expected to 
optimize benefits and risks. However, it is also associated with high screening costs and 
imprecise risk prediction in primary prevention, especially when calculating long-term risk. 
Primary prevention should also consider the recognized relationship between modifiable risk 
factors (BP, LDL, cholesterol, smoking) and CVD [21-23]. The use of drugs to reduce the 
severity of these risk factors is a complementary approach. Long-term administration of multiple 
drugs to “healthy” asymptomatic individuals in order to lower multiple risk factor levels is 
impractical and it can succeed only when individuals are exceptionally motivated. However, a 
fixed-dose combination drug, administered once daily (i.e., a polypill), which simultaneously 
modifies several risk factors and probably reduces CVD may enjoy an enthusiastic uptake. In 
people without CVD, age is the most discriminatory screening factor. Therefore, the use of a 
polypill in people aged >55 years, (particularly in those with at least one additional risk factor) 
could prevent the majority of CVD events in both high- and low-income countries [7]. 
Several clinical trials have assessed the utility of the polypill in primary prevention. A 
phase II, double blind, randomized clinical non-inferiority trial (The Indian Polycap Study 
[TIPS]) evaluated the efficacy, tolerability, and safety of Polycap in over 2000 individuals in 50 
centers in India. This study demonstrated that the Polycap was non-inferior to its individual 
components in lowering blood pressure and heart rate (a surrogate for β-blockade), but it did not 
reduce LDL concentrations to the same extent as simvastatin monotherapy (27 vs 32 mg/dL; p = 
0.04) [24]. Another double-blind, randomized, placebo-controlled, cross over trial analyzed the 
efficacy of a polypill containing amlodipine 2.5 mg, losartan 25 mg, HCTZ 12.5 mg, and 
simvastatin 40 mg in 86 individuals over the age of 50 years, treated for 12 weeks followed by 
12 weeks crossover to placebo [25]. Polypill therapy was associated with reductions in DBP by 
9.8 mm Hg, systolic blood pressure (SBP) by 17.9 mm Hg, and LDL by 1.4 mmol/L. This would 
be expected to result in relative risk reductions of 72% in CVD and 64% in stroke [26]. The fact 
that the participants in this trial were recruited from patients already taking simvastatin and blood 
pressure lowering medications may have contributed to the remarkable adherence rate (98% of 
participants took more than 85% of their pills). 
Despite some attempts with prehypertension therapy, whether BP-lowering drugs may 
prove beneficial in individuals without CVD, including in individuals with “normal” baseline BP 
levels, remains unknown. 
Clinical trials have demonstrated that a combination pill was well tolerated and that it 
effectively reduced blood pressure and LDL-cholesterol. This resulted in a considerable 
reduction in the calculated risk of CVD and stroke [3]. Despite the fact that these studies seem to 
support the use of a low-dose polypill for the primary prevention of CVD, there are still some 
unresolved issues. Firstly, there are no results from long-term trials indicating actual benefits in 
terms of morbidity and mortality. It is likely that the ongoing TIPS-3 and prevention of 
Cardiovascular Disease in Middle-aged and Elderly Iranians using a single polypill 
(POLYIRAN) trials will be able to provide data regarding actual benefits associated with the use 
of the polypill in primary prevention of CVD. In the POLYIRAN trial, the effects of the polypill 
administration will be compared with minimal and usual care over a period of 5 years [27]. The 
TIPS-3 study will compare the effects of Polycap and placebo on a composite of major CVD 
(CV death, non-fatal stroke, non-fatal myocardial infarction [MI]), heart failure, resuscitated 
cardiac arrest, or revascularization with evidence of ischemia in 5000 participants (without 
known heart disease or prior stroke and without a clear indication or contraindication to any of 
the study medications) [28]. The estimated study completion date is March 2020. Another 
problem of primary prevention is that asymptomatic individuals are unlikely to adhere to a 
lifelong regimen of medical therapy. Moreover, some consider it to be unethical to treat large 
portion of the population who appear to be “healthy” and “asymptomatic”. Additionally, there is 
no convincing evidence to support the cost-effectiveness of the polypill in people with low or 
unknown risk factors [3]. Other concerns associated with the use of polypills in primary 
prevention relate to its non-specific ‘scattergun’ approach, which would expose people at lower 
risk to lifelong treatment [29]. 
Primary prevention is associated with numerous issues. Some evidence suggests that 
aspirin may exert different effect in women and men [30]. The results of the completed Women’s 
Health Study (WHS), of low-dose aspirin (100 mg every other day) compared with placebo, 
demonstrated no reduction in all-cause mortality or fatal and non-fatal myocardial infarction 
[29].  
A randomized trial of 2.5 mg/day of folic acid (the proposed polypill dosage is 0.8 
mg/day) demonstrated that this was not associated with a reduction in the combined trial end 
point of stroke, coronary events, and death in patients with earlier cerebral infarction [31]. In 
contrast, in the large China Stroke Primary Prevention Trial (CSPPT) randomized clinical trial, 
the combined use of enalapril and folic acid considerably reduced the risk of first stroke, 
compared with enalapril alone. This suggests benefits from folate use among adults with 
hypertension and low baseline folate levels [32]. The reason why folic acid has not been 
demonstrated to reduce myocardial infarction may be associated with the fact that aspirin may 
mask the effect of folic acid due to a shared mechanism of action. Vitamin B therapy lowers 
plasma total homocysteine concentrations [33], however, the reduction in homocysteine level 
may not add to the effect of aspirin (and possibly other antiplatelet drugs) in preventing ischemic 
heart disease [34]. Homocysteine exerts a thrombotic effect through its action on platelet 
function, while aspirin irreversibly blocks the formation of thromboxane 29 in platelets, 
inhibiting platelet activation and platelet aggregation [35]. Due to the fact that homocysteine 
exerts a thrombotic effect through its action on platelet function, concomitant treatment with 
aspirin could diminish or negate the antiplatelet effect of lowering homocysteine [34]. Therefore, 
folic acid could play a role in the primary prevention of ischemic heart disease in patients who 
do not take aspirin routinely, but not in secondary prevention, when aspirin is administered 
routinely. The hypothesis that aspirin decreases or negates the antiplatelet effect of homocysteine 
lowering is supported by the results of a meta-analysis that demonstrated a statistically 
significant difference in risk reduction between trials with the lowest and highest prevalence of 
concomitant antiplatelet therapy (p = 0.037) [34]. Moreover, meta-analysis of three large trials: 
Vitamin Intervention for Stroke Prevention (VISP), VITAmins TO Prevent Stroke (VITATOPS), 
and Heart Outcomes Prevention Evaluation 2 (HOPE-2) revealed that in patients who were not 
taking antiplatelet therapy, homocysteine lowering with B-vitamins was associated with a 
significant reduction (29%) in overall stroke risk [36].  
 
1. 2.3. Use of the Polypill in secondary prevention. 
The use of aspirin, statins, ß-blockers, and ACE inhibitors/ARBs in the secondary 
prevention of CVD is beneficial. A large number of studies have demonstrated the reduction in 
cardiovascular-related mortality in individuals receiving appropriate medical therapy [3, 7, 37]. 
Multiple obstacles stand in the way of better implementation of secondary prevention strategies. 
Firstly, numerous studies indicate that therapies with proven efficacy are not prescribed to all 
who may benefit from them. According to the third European Action on Secondary Prevention 
Through Intervention to Reduce Events (EUROASPIRE III) survey in nine European countries, 
the prevalence of smoking is 17%, obesity 35%, uncontrolled BP 56%, and elevated cholesterol 
25% among patients with ischemic heart disease, while the administration of statins and ACE 
inhibitors/ARBs is relatively low: 71% and 78%, respectively [38].  
The use of appropriate drugs is even lower in developing countries. The World Health 
Organization study on Prevention of Recurrence of Myocardial Infarction and Stroke 
(WHO-PREMISE) survey was carried out in ten low- and middle-income countries and 
demonstrated that only 81.2% of patients with IHD and 70.6% of patients with cerebrovascular 
disease were prescribed aspirin, 48.1% and 22.8% β-blockers, 39.8% and 37.8% ACE inhibitors, 
and 29.8% and 14.1% statins [39]. The situation is worst in rural areas. A community-based 
study performed in 53 villages in India revealed that only 14% patients with IHD or 
cerebrovascular disease were taking aspirin, 41% a BP-lowering drug, and 5% a 
cholesterol-lowering medication [40].  
Secondly, due to numerous factors (psychological, social, cultural, economic, and clinical 
factors related to patients, healthcare providers, healthcare systems, and their interactions) 
long-term adherence to prescribed medications is poor - often <50% [7, 41]. Patient adherence to 
long-term therapies is among the most important public health priorities of the European Union 
and is a concern for the medical community [42]. Appropriate medical therapy for the secondary 
prevention of CVD is often associated with the need to take multiple medications. A group of 
patients who were administered four evidence- based medications after hospitalization for acute 
coronary syndrome (ACS) had considerably higher survival after 2 years than a group of patients 
who only received only one of these medications [43]. On the other hand, adherence has been 
revealed to diminish proportionally to the number of drugs taken by the patient. In patients who 
were hospitalized for coronary artery disease, the adherence to prescribed medications can be as 
low as 40% [44,45]; this may result in a 50% to 80% relative increase in the risk of mortality 
[46]. The polypill has the potential to resolve the problem of non-adherence to medicines used in 
the secondary prevention of CVD. A beneficial effect of the polypill on adherence was 
demonstrated in the Use of a Multidrug Pill in Reducing Cardiovascular Events (UMPIRE) 
study, in which medication adherence was compared in a group of patients receiving a polypill 
and a group receiving usual therapy. The participants had established CVD or a calculated 5-year 
CVD risk of >15% [47]. In this study, 2004 participants received a combination of aspirin 75 
mg, simvastatin 40 mg, lisinopril 10 mg, and atenolol 50 mg or HCTZ 12.5 mg) or usual medical 
therapy over 15 months. This study demonstrated that adherence was 33% better in the polypill 
group, and that this was associated with a reduction of SBP (2.6 mmHg) and LDL-cholesterol 
(4.2 mg/dL).  
Finally, cost and affordability pose an important barrier, especially in low-income 
countries. Despite the fact that drugs used in secondary prevention are generally cost-effective, 
in middle- and low-income countries the cost of a 1-month supply of standard generic secondary 
prevention drugs ranges from 1.5 to 18.4 days' wages of government workers. Therefore some 
patients cannot afford the drugs they require [7,48,49]. The Prospective Urban Rural 
Epidemiology (PURE) study, which investigated the use of medications for secondary 
prevention, in adults with a history of CVD events across countries of varying wealth 
demonstrated suboptimal overall use of antiplatelet drugs 25.3%, ß-blockers 17.4% and statins 
14.6%) [50]. The observation that the use of appropriate medications decreased gradually with 
diminishing economic status was not surprising. Therefore, there is a large treatment gap 
between high- and low-income countries that is most clearly depicted by the difference in rates 
of statin use in high-income (66.5%) and low-income (3.3%) countries. Affordability is an 
important issue in the treatment gap. Mendis et al. [49] revealed that 1 month of multiple drug 
therapy could cost between 5.1 and 18.4 days of wages in low- and middle-income countries 
(LMICs). Therefore the use of a single polypill, which costs less than 50% of the sum of the 
prices of its components purchased separately, may improve the affordability, and in 
consequence improve the adherence [51]. Furthermore, the application of a Markov model 
demonstrated that a combination pill would be cost-effective in secondary prevention regardless 
of the socioeconomic level of the target population [48]. 
Trials indicate that fixed-dose combination therapy reduces lipid levels (using statins) 
and blood pressure (using angiotensin-converting enzyme inhibitors, ß-blockers and diuretics) to 
the same extent as giving each drug separately [52]. Also, the effects of aspirin on the 
suppression of markers of thromboxane 5 are similar when it is administered separately or in 
combination with the other components of the polypill [53]. 
The aim of cross-sectional Fixed-Dose Combination Drug for Secondary Cardiovascular 
Prevention (FOCUS) study (Phase 1) [54] was to identify factors that interfere with appropriate 
adherence to CV medications for secondary prevention after an acute MI. Moreover, in the 
controlled trial (Phase 2) the effect of a polypill (containing aspirin 100 mg, simvastatin 40 mg, 
and ramipril 2.5, 5, or 10 mg) were compared with the three drugs given separately in terms of 
adherence, blood pressure, and low-density lipoprotein cholesterol. Safety and tolerability were 
also measured over a 9 months follow-up period. In the first phase of this study, overall 
adherence to CV medications, defined as self-reported Morisky-Green questionnaire (MAQ) 
score of 20, was 45.5%. Lack of adherence (MAQ <20) was associated with younger age, 
depression, being on a complex medication regimen, poorer health insurance coverage, and a 
lower level of social support. In the second phase of the study, adherence was shown to be 
improved in group receiving polypill in comparison to the group receiving separate medications 
after 9 months of follow-up: 50.8% versus 41% (p=0.019; intention-to-treat population) and 
65.7% vs. 55.7% (p=0.012; per protocol population). In relation to treatment effects, no 
treatment difference was found at follow-up with respect to mean systolic blood pressure (129.6 
mm Hg vs. 128.6 mm Hg), mean low-density lipoprotein cholesterol levels (89.9 mg/dl vs. 91.7 
mg/dl), serious adverse events (23 vs. 21), or death (1, 0.3% in each group). There were no 
significant differences in adverse events in both groups (32% of patients in the control group vs. 
35% in the polypill group; serious adverse events 6.6% in the control group vs. 6% in the 
polypill group) [54]. 
The Heart Outcomes Prevention Evaluation (HOPE)-3 trial, which assessed the concept 
of combined BP and cholesterol lowering in individuals without vascular disease and with 
average BP and cholesterol levels demonstrated that fixed-dose treatment with low-dose statin 
therapy, but not BP agents, is superior to placebo in reducing long-term CV events in an 
intermediate-risk population [55]. This trial was conducted in 256 centers in 22 countries in 
North and South America, Europe, Africa, Asia, and Australia and included 12,705 patients at 
moderate risk (men aged 55 years and women aged 65 years with one risk factor or women aged 
60 years with two risk factors) The expected annual event rate in the placebo group was 0.9% to 
1%. Patients were randomized to receive rosuvastatin 10 mg/d alone, a fixed-dose combination 
of candesartan 16 mg/hydrochlorothiazide 12.5 mg/d or rosuvastatin + candesartan + HCTZ. The 
fixed-dose combination of candesartan 16 mg + HCTZ 12.5 mg daily was not superior to 
placebo in reducing CV events despite a 6 mm decrease in SBP and a 3 mm decrease in DBP. 
The fixed-dose combination of all three drugs appeared to have CV benefits that were mostly 
similar to those observed with rosuvastatin alone [55].  
The PolyIran Study [56] is an important ongoing trial assessing the effectiveness of a 
polypill containing hydrochlorothiazide (12.5mg), enalapril (5mg) or valsartan (40mg), 
atorvastatin (20mg), aspirin (81mg) in persons ≥50 years old with or without prior CVD. The 
primary endpoint is time to first major CV event (during a 5-year follow-up). The trial is due to 
be completed still in 2018. Another large trial, which will report after its completion in 2018 is 
the Heart Outcomes Prevention and Evaluation 4 (HOPE-4) study [57]. This open-label, parallel, 
cluster randomized controlled pragmatic trial is evaluating an intensive CV risk detection and 
control programme. The study is being carried out in Canada, Colombia, Malaysia in over 30 
community clusters. The effects of a combination of blood pressure lowering medication (2-3 
components) plus a statin (provided separately) will be assessed in patients ≥50 years old with 
SBP ≥160 mmHg or SBP 140-159 mmHg and diagnosis of hypertension or taking anti-HTs or 
SBP ≥130 mmHg and diagnosis of diabetes or taking diabetes medication. Framingham Risk 
Score (FRS) is the primary endpoint. Finally, the Secondary Prevention of Cardiovascular 
Disease in the Elderly (SECURE) study [58], which is a European collaborative project funded 
by the EU Framework Programme for Research and Innovation, will be testing the efficacy of a 
fixed-dose combination (FDC) polypill Trinomia (aspirin (100mg), atorvastatin (40 or 20mg), 
ramipril (2.5, 5, 10mg) for secondary cardiovascular prevention in the elderly population (≥65 
years old). Its main objective is to assess the potential benefit of the FDC as a component of a 
cost-effective, globally available and comprehensive treatment strategy for secondary prevention 
of cardiovascular events (death from cardiovascular causes, non-fatal myocardial infarction, 
stroke, and hospitalization requiring revascularization) as compared to standard therapy (the 
three components of the polypill given separately). Primary endpoint in this study is major 
adverse cardiovascular events (MACE) at 6, 12, 18 and 24 months. This study will be completed 
in January 2020. 
 
1. 3. Conclusions 
Recent studies have indicated that polypills are useful for the primary prevention of 
CVD. They act by significant reducing both BP and LDL-C concentrations. It has also been 
demonstrated that polypills are beneficial in secondary prevention, they improve adherence and 
are well tolerated. The ongoing trials: HOPE-4, OMS, PILL, SECURE, TIPS 3 and UMPIRE 
should help to reach a final decision concerning the safety and efficacy of the polypills.  
1. 4. Expert Opinion 
The results of the five studies described above, indicates that the polypill is useful for the 
primary prevention of CVD. It works by reducing main CVD risk factors - BP and LDL-C level 
[59]. Huffman et al. [60] performed an analysis of 13 polypill trials (9059 participants) and 
demonstrated that all polypills used improved adherence, were well tolerated, and reduced risk 
factor levels. These benefits have been observed in both primary and secondary prevention.  
As indicated, the polypill may have several advantages. First, it enables the avoidance of 
complex treatment algorithms to identify individuals for therapy. It increases the ease of 
prescribing and eliminates the need for dose titration of each drug [7]. This advantage remains 
unproven, however, a study of high-risk patients with IHD and/or diabetes mellitus receiving a 
“cardioprotective bundle” demonstrated that the simplified regimen (fixed doses, minimal 
physician visits, laboratory tests, and dose titration) led to diminished risk of hospitalizations for 
IHD or stroke within 1 year [61].  
The use of polypill may enhance adherence due to the fact that patient is taking one tablet 
or capsule instead of several. In patients receiving medicines for the secondary prevention of CV 
prevention patients, compliance decreases over time. This has an important impact on health, 
morbidity and healthcare costs [62]. The results of a post-hoc analysis of the SPACE 
Collaboration data set suggests that the adherence benefits of polypills will outweigh the loss of 
potency associated with the use of low doses of the individual components [63]. The 
effectiveness of the combined use of two antihypertensive agents (ARB and diuretic) at a half 
dose and statin in the primary prevention of CVD in individuals with intermediate risk and 
without CVD was confirmed in the recent HOPE-3 study [62,64]. Not all patients with CV 
problems are administered all recommended drugs. Therefore, administration of a polypill 
containing all necessary components (even in reduced doses) may be associated with benefits. 
Finally, the low dose of the component drugs in polypills may be associated with a lower 
frequency of side effects. This benefit may outweigh the loss of potency. In the case of 
statin-therapy, this may be especially important. Real and perceived adverse effects of statin 
therapy lead to discontinuation of therapy with consequent poor outcomes. This phenomenon of 
‘statin intolerance’ can be managed in many cases with lower doses of statin (or alternate day 
dosing), whilst retaining lipid lowering efficacy to a large extent [65,66]. A low-dose of statin in  
a polypill is therefore likely to lower CV risk bur minimise adverse effects.   However, in the 
case of primary prevention, subjects who feel healthy may not be motivated to use medications 
for a long time. Therefore, even minor side effects to one component of the polypill may result in 
its discontinuation and the loss of benefit from all component drugs.  
The cost-effectiveness of polypills in comparison to separate administration of the 
individual components has been demonstrated in various populations. According to estimates, 
the costs of a polypill containing generic components is ~$1 a day in developed and 20 cents in 
developing countries, which is much lower than the costs of individual drugs [7]. Cost-reduction 
may be associated with reduced expenditures on packaging, distribution, and lower marketing 
costs as well as fewer physician visits and laboratory tests. One study designed to estimate the 
health benefits and cost-effectiveness of a polypill intervention (aspirin 100 mg, atorvastatin 20 
mg, ramipril 10 mg) compared with multiple monotherapy for secondary prevention of 
cardiovascular events in adults with a history of myocardial infarction demonstrated that over a 
10-year period, the use of the cardiovascular polypill would avoid 46 non-fatal and 11 fatal 
cardiovascular events per 1000 patients treated [42]. However, the real cost of a polypill will not 
be known before a product gains marketing authorization. It will depend on the costs of the “raw 
ingredients” and packaging but will also include costs of product formulation, research and 
development, registration, marketing and distribution, as well as “profit” for manufacturers [7].  
Healthcare regulators are implementing unnecessary barriers to the licensing of polypills 
when the individual components are already licensed products. In general, no clearly defined 
pathway to regulatory approval is available apart from a ‘straight substitution’ indication based 
on bioequivalence data [67]. The requirement to conduct additional tests and randomized clinical 
trials not only delays the introduction of new treatments, but also increases costs. Recently the 
FDA set up a Combination Products Policy council aiming at establishing unified requirement 
for approving combination therapies. This approach seems to be a step in a right direction [67]. 
The implementation of the polypill is also limited due to the existence of patents for its 
components. In Canada and the United States, the availability of off-patent cardiovascular 
medication was estimated to be only 40% [68]. The potential usefulness of a polypill may be also 
reduced due to an ongoing preference for tailored treatment, resulting in a reluctance of health 
care providers to prescribe polypills. However, evidence indicates that more and more physicians 
are recognizing the potential benefits of the polypill, which improves adherence and can be 
successfully used in the secondary prevention of CVD [67]. Another issue for health care 
providers is the lack of universal guidelines supporting the use of polypills [67]. The absence of 
a generally available polypill, nearly 20 years after the concept was proposed, represents a failure 
of the medical community to grasp an enormous opportunity to prevent disease.  
However, the composition of the “ideal” polypill remains to be confirmed. There are 
many unanswered questions. Are the ingredients of the polypill sufficient to achieve anticipated 
effects in primary and secondary protection? Is there a need to add some new element or to 
modify the old ones? Should the pill contain aspirin which has a negligible role in primary 
prevention and which increases the risk of gastrointestinal bleeding and the risk of allergy? The 
Medicines and Health Products Regulatory Agency has decided that it is reasonable to avoid 
using ACE-inhibitor in polypill due to its side effects. An Angiotensin receptor blocker (losartan) 
seems to be a better choice since it exerts similar blood pressure lowering effect as an 
ACE-inhibitor and rarely causes a cough [69]. The debate over the use of aspirin in polypills is 
still open. Aspirin is undoubtedly effective in secondary prevention, however, its benefits may be 
very limited in primary prevention when the absolute risk is low due to the cholesterol and blood 
pressure reduction achieved by the use of other components of the polypill. It is also unclear 
whether the benefits of aspirin outweigh the harms [69]. Recent finding that aspirin may protect 
against cancer may tip the scales in favor of aspirin. 
The polypill may not be suitable for all who wish to benefit from it. Consideration should 
be given to producing a small range of polypills to make them as widely available as possible  
[70,71]. For example, a polypill without a β-blocker for would be useful in persons with asthma. 
A polypill with an increased dose of statin may be useful for those in whom very low 
LDL-cholesterol levels are desirable [7]. Moreover, patients at extremely high risk (e.g., those 
with very aggressive manifestations of atherothrombotic disease) as well as those with side 
effects to multiple medications may still require individualized therapy. The introduction of 
many polypills would further complicate the situation and therefore it seems that the use of two 
polypills for primary and secondary prevention (including aspirin and a beta-blocker) may be 
reasonable. 
On 23rd May 2016, the 2016 European Guidelines on cardiovascular disease prevention 
in clinical practice by the European Society of Cardiology (ESC), advised that the polypill could 
be considered as a treatment option, as part of a comprehensive CVD prevention strategy in 
certain patients [72].  
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ARTICLE HIGHLIGHTS BOX 
•  The polypill has been shown to be effective in the primary prevention of 
cardiovascular disease (CVD). 
•  The polypill makes prescribing easier by reducing the need for complex treatment 
algorithms and dose titration.  
•  The use of polypills may enhance adherence by simplifying the dosing regimen. 
The adherence benefits of polypills outweigh the loss of effectiveness associated with the 
use of low doses of individual components. 
•  There are still many issues that need to be addressed before the polypill can be 
routinely used. There is no clearly defined pathway to regulatory approval. 
•  Healthcare Regulators are imposing unnecessary barriers to the licensing of 
polypills. Furthermore, the implementation of the polypill is made difficult by the 
existence of patents for its component drugs. The composition of “ideal” polypill remains 
to be confirmed. 
•  On May 2016, the European Guidelines on cardiovascular disease prevention in 
clinical practice by the European Society of Cardiology advised that the polypill could be 
considered as a treatment option in certain patients., as part of a comprehensive CVD 
prevention strategy.  
 
REFERENCES: 
1. World Health Statistics. 2011. Cardiovascular diseases (CVDs) fact sheet. Available at: 
http://www.who.int/mediacentre/factsheets/fs317/en/. Accessed on 20.03.2018 
2. Mendis S, Puska P, Norrving B. Global Atlas on Cardiovascular Disease Prevention and 
Control. Geneva, Switzerland: World Health Organization; 2004. 
3. Wiley B, Fuster V. The Concept of the Polypill in the Prevention of Cardiovascular Disease. 
Annals of Global Health 2014;80:24-34 
4. Yusuf S, Hawken S, Ounpuu S, et al. Effect of potentially modifiable risk factors associated 
with myocardial infarction in 52 countries (the INTERHEART study): case control study. 
Lancet. 2004;364:937e52 
**5. Wald NJ, Law MR. A strategy to reduce cardiovascular disease by more than 80%. BMJ 
2003;326:1419. 
(the first publication on polypill) 
6. Castellano JM, Sanz G, Fernandez Ortiz A, et al. A Polypill Strategy to Improve Global 
Secondary Cardiovascular Prevention From Concept to Reality* J Am Coll Cardiol 
2014;64:613–21 
7. Lonn E, Bosch J, Teo KK, et al. The Polypill in the Prevention of Cardiovascular Diseases 
Key Concepts, Current Status, Challenges, and Future Directions. Circulation. 
2010;122(20):2078-88. 
8. Clarke R, Halsey J, Lewington S, et al. for the B-Vitamin Treatment Trialists' Collaboration. 
Effects of lowering homocysteine levels with B vitamins on cardiovascular disease, cancer, and 
cause-specific mortality: meta-analysis of 8 randomized trials involving 37,485 individuals. Arch 
Intern Med. 2010;170:1622–1631. 
9. Baigent C, Blackwell L, Collins R, et al. Antithrombotic Trialists' (ATT) Collaboration. 
Aspirin in the primary and secondary prevention of vascular disease: collaborative meta-analysis 
of individual participant data from randomised trials. Lancet. 2009;373:1849–1860. 
10. McNeil JJ, Wolfe R, Woods RL et al. ASPREE Investigator Group. Effect of Aspirin on 
Cardiovascular Events and Bleeding in the Healthy Elderly. N Engl J Med. doi: 
10.1056/NEJMoa1805819 
11. Gaziano JM, Brotons C, Coppolecchia R, et al. ARRIVE Executive Committee. Use of 
aspirin to reduce risk of initial vascular events in patients at moderate risk of cardiovascular 
disease (ARRIVE): a randomised, double-blind, placebo-controlled trial. Lancet. 2018 doi: 
10.1016/S0140-6736(18)31924-X 
12. ASCEND Study Collaborative Group. Effects of Aspirin for Primary Prevention in Persons 
with Diabetes Mellitus. N Engl J Med. 2018 doi: 10.1056/NEJMoa1804988.  
13. Rothwell PM, Cook NR, Gaziano JM, et al. Effects of aspirin on risks of vascular events and 
cancer according to bodyweight and dose: analysis of individual patient data from randomised 
trials. Lancet. 2018 Aug 4;392(10145):387-399. 
14. Kearney PM, Blackwell L, Collins R, et al. Cholesterol Treatment Trialists' (CTT) 
Collaborators. Efficacy of cholesterol-lowering therapy in 18,686 people with diabetes in 14 
randomised trials of statins: a meta-analysis. Lancet. 2008;371:117–125. 
15. Armitage J. The safety of statins in clinical practice. Lancet. 2007;370:1781–1790 
16. Sattar N, Preiss D, Murray HM, et al. Statins and risk of incident diabetes: a collaborative 
meta-analysis of randomised statin trials. Lancet. 2010;375:735–742 
17. Law MR, Wald NJ, Rudnicka AR. Quantifying effect of statins on low-density lipoprotein 
cholesterol, ischaemic heart disease, and stroke: systematic review and meta-analysis. BMJ. 
2003;326:1423e9. 
18. Law MR, Wald NJ, Moris JK, Jordan RE. Value of low dose combination treatment with 
blood pressure lowering drugs: analysis of 354 randomised trials. BMJ. 2003;326:1427–1431 
19. Patel A, Shah T, Shah G, et al. Preservation of bioavailability of ingredients and lack of 
drug-drug interactions in a novel five-ingredient polypill (Polycap). Am J Cardiovasc Drugs. 
2010; 10: 95–103  
20. Ebrahim S, Beswick A, Burke M, Davey SG. Multiple risk factor interventions for primary 
prevention of coronary heart disease. Cochrane Database Syst Rev. 2006;4:CD001561. 
21. Law MR, Wald NJ. Risk factor thresholds: their existence under scrutiny. BMJ. 
2002;324:1570–1577.  
22. Teo KK, Ounpuu S, Hawken S, et al. INTERHEART Study Investigators. Tobacco use and 
risk of myocardial infarction in 52 countries in the INTERHEART study: a case-control study. 
Lancet. 2006;368:647–658. 
23. Lewington S, Clarke R, Qizilbash N, et al. Prospective Studies Collaboration. Age-specific 
relevance of usual blood pressure to vascular mortality: a meta-analysis of individual data for 
one million adults in 61 prospective studies. Lancet. 2002;360:1903–1913. 
**24. The Indian Polycap Study. Effects of a polypill (Polycap) on risk factors in middle-aged 
individuals without cardiovascular disease (TIPS): a phase II, double-blind, randomised trial. 
Lancet. 2009; 373: 1341–1351 
(presents results of polypill use in a randomized trial) 
**25. PILL Collaborative Group, Rodgers A, Patel A, Berwanger O, et al. An international 
randomised placebo-controlled trial of four-component combination pill (“polypill”) in people 
with raised cardiovascular risk. PLoS One. 2011; 6: e19857 
(presents results of polypill use in a randomized trial) 
26. Wald DS, Morris JK, Wald NJ. Randomized polypill crossover trial in people aged 50 and 
over. PLoS One. 2012; 7: e41297 
**27. Tehran University of Medical Sciences. Prevention of Cardiovascular Disease in 
Middle-aged and Elderly Iranians Using a Single PolyPill (PolyIran).In: ClinicalTrials.gov 
[Internet].Available from: http://clinicaltrials.gov/ct2/show/NCT01271985. Accessed March 12, 
2018. 
(presents results of polypill use in a trial) 
**28. Population Health Research Institute;The International Polycap Study 3 (TIPS-3). In: 
ClinicalTrials.gov [Internet]. Available from: 
http://clinicaltrials.gov/ct2/show/study/NCT01646437 Accessed March 12, 2018. 
(presents results of polypill use in a trial) 
**29. Ridker PM, Cook N, Lee I, et al. A randomised trial of low-dose aspirin in the primary 
prevention of cardiovascular disease in women. N Engl J Med 2005;352: 1293-304. 
(presents results of polypill use in a randomized trial) 
30. Fahey T, Brindle P, Ebrahim S. The polypill and cardiovascular disease: May be appropriate 
for secondary, but perhaps not for primary prevention. BMJ: British Medical Journal 
2005;330(7499):1035-1036. 
31. Toole J, Malinow MCL, Spence J, et al. Lowering homocysteine in patients with ischemic 
stroke to prevent recurrent stroke, myocardial infarction and death. The vitamin intervention for 
stroke prevention (VISP) randomized controlled trial. JAMA 2004;291: 565-75 
32. Huo Y, Li J, Qin X, et al. Efficacy of folic acid therapy in primary prevention of stroke 
among adults with hypertension in China: the CSPPT randomized clinical trial. JAMA. 2015 Apr 
7;313(13):1325-35.  
33. Spence JD, Yi Q, Hankey GJ. B-vitamins in stroke prevention: time to reconsider. Lancet 
Neurol. 2017;16(9):750-760. 
34. Wald DS, Morris JK, Wald NJ (2011) Reconciling the Evidence on Serum Homocysteine 
and Ischaemic Heart Disease: A Meta-Analysis. PLoS ONE 6(2): e16473 
35. Vane JR, Botting RM. The mechanism of action of aspirin. Thromb Res 2003;110: 255–8 
36. Park JH, Saposnik G, Ovbiagele B, Markovic D, Towfighi A Effect of B-vitamins on stroke 
risk among individuals with vascular disease who are not on antiplatelets: A meta-analysis. Int J 
Stroke. 2016 Feb;11(2):206-11 
37. Ford EA, Ajani UA, Croft JB, et al. Explaining the decline in coronary mortality in the 
United States between 1980 and 2000. N Engl J Med. 2007; 356: 2388–2398 
38. Kotseva K, Wood D, De Backer G, et al. EUROASPIRE III: a survey on the lifestyle, risk 
factors and use of cardioprotective drug therapies in coronary patients from 22 European 
countries. Eur J CardiovascPrevRehabil. 2009; 16: 121–137 
39. Mendis S, Abegunde D, Yusuf S, et al. WHO study on Prevention of Recurrences of 
Myocardial Infarction and Stroke (WHOPREMISE). Bull World Health Organ. 
2005;83:820–829 
40. Joshi R, Chow CK, Raju PK, et al. Fatal and non-fatal cardiovascular disease and the use of 
therapies for secondary prevention in a rural region of India. Circulation. 2009;119:1950–1955 
41. Osterberg L, Blaschke T. Adherence to medication. N Engl J Med. 2005;353:487–497. 
*42. Barrios V, Kaskens L, Castellano JM, et al. Usefulness of a Cardiovascular Polypill in the 
Treatment of Secondary Prevention Patients in Spain: A Cost-effectiveness Study. Rev 
EspCardiol (Engl Ed). 2017;70(1):42-49 
(study presenting economic analysis of polypill use) 
43. Lahoud R, Howe M, Krishnan SM, et al. Effect of use of combination evidence-based 
medical therapy after acute coronary syndromes on long-term outcomes. Am J Cardiol. 2012; 
109: 159–164 
44. Jackevicius CA, Mamdani M, Tu JV. Adherence with statin therapy in elderly patients with 
and without acute coronary syndromes. JAMA. 2002; 288: 462–467 
45. Newby LK, LaPointe NMA, Chen AY, et al. Long-term adherence to evidence-based 
secondary prevention therapies in coronary artery disease. Circulation. 2006; 113: 203–212 
46. Ho PM, Magid DJ, Shetterly SM, et al. Medication non-adherence is associated with a broad 
range of adverse outcomes in patients with coronary artery disease. Am Heart J. 2008; 155: 
772–779 
47. Thom SA. Use of a Multidrug Pill in Reducing Cardiovascular Events (UMPIRE). Paper 
presented at: AHA Scientific Sessions. November 5, 2012. Los Angeles, California. 
48. Gaziano TA, Opie LH, Weinstein MC. Cardiovascular disease prevention with a multidrug 
regimen in the developing world: a cost-effectiveness analysis. Lancet. 2006; 368: 679–686 
49. Mendis S, Fukino K, Cameron A, et al. The availability and affordability of selected essential 
medicines for chronic diseases in six low- and middle-income countries. Bull World Health 
Organ. 2007; 85: 279–288 
50. Yusuf S, Islam S, Chow CK, et al. Use of secondary prevention drugs for cardiovascular 
disease in the community in high-income, middle-income, and low-income countries (the PURE 
Study): a prospective epidemiological survey. Lancet. 2011; 378: 1231–1243 
51. Sanz G,Fuster V. Polypill and global cardiovascular health strategies. Semin Thoracic 
Surgery. 2011; 23: 24–29 
52. Huffman MD, Yusuf S. Polypills. Essential Medicines for Cardiovascular Disease Secondary 
Prevention? J Am CollCardiol 2014;63:1368–70 
53. Elley CR, Gupta AK, Webster R, et al. The efficacy and tolerability of ‘polypills’: 
meta-analysis of randomised controlled trials PLoS One 2012;7:e51245 
54. Castellano JM, Sanz G, Peñalvo JL, et al. A Polypill Strategy to Improve Adherence Results 
From the FOCUS Project. J Am CollCardiol 2014;64:2071–82 
55. Yusuf S, Bosch J, Dagenais G, et al; HOPE-3 Investigators. Cholesterol Lowering in 
Intermediate-Risk Persons without Cardiovascular Disease. N Engl J Med. 
2016;374(21):2021-31.  
**56. Tehran University of Medical Sciences, Prevention of Cardiovascular Disease Using a 
Single PolyPill in an Urban Population - Focus on Liver-Related Variables. (PolyIran-L)In: 
ClinicalTrials.gov [Internet]. Bethesda (MD): National Library of Medicine (US). Available 
from: https://clinicaltrials.gov/ct2/show/NCT01245608; Accessed: 12 March 2018 
(presents results of polypill use in a trial) 
**57. Hamilton Health Sciences Corporation. Heart Outcomes Prevention and Evaluation 4 
(HOPE-4). In: ClinicalTrials.gov [Internet]. Bethesda (MD): National Library of Medicine (US). 
Available from: https://clinicaltrials.gov/ct2/show/NCT01826019; Accessed: 12 March 2018 
58. http://www.secure-h2020.eu/ Accessed: 12 March 2018 
(presents results of polypill use in a clinical trial) 
59. Chrysant SG, Chrysant GS. Usefulness of the polypill for the prevention of cardiovascular 
disease and hypertension. Current Hypertension Reports 2016; 18: 14 
**60. Huffman MD, Xavier D, Perel P. Uses of polypills for cardiovascular disease and evidence 
to date. Lancet 2017; 389: 1055–1065 
(analysis of 13 polypill trials) 
61. Dudl RJ, Wang MC, Wong M, Bellows. Preventing myocardial infarction and stroke with a 
simplified bundle of cardioprotective medications. Am J Manag Care. 2009;15:e88–e94. 
62. López-Jaramillo P, González-Gómez S, Zarate-Bernal D, et al. Polypill: an affordable 
strategy for cardiovascular disease prevention in low-medium-income countries. Ther Adv 
Cardiovasc Dis. 2018;12(6):169-174 
63. Webster R, Bullen C, Patel A, Selak V, Stepien S, Thom S, Rodgers A. Impact of switching 
to polypill based therapy by baseline potency of medication: Post-hoc analysis of the SPACE 
Collaboration dataset. Int J Cardiol. 2017;249:443-447 
64. Lonn E, Bosch J, Pogue J, et al. Novel approaches in primary cardiovascular disease 
prevention: The HOPE-3 trial rationale, design, and participants’ baseline characteristics. Can J 
Cardiol 2016; 32: 311–318 
65. Banach M, Mikhailidis DP. Statin Intolerance: Some Practical Hints. Cardiol Clin. 2018 
May;36(2):225-231.  
66. Awad K, Mikhailidis DP, Toth PP, et al. Lipid and Blood Pressure Meta-analysis 
Collaboration (LBPMC) Group. Efficacy and Safety of Alternate-DayVersus Daily Dosing of 
Statins: a Systematic Review and Meta-Analysis. Cardiovasc Drugs Ther. 2017 
Aug;31(4):419-431.  
67. Brimble, M, Tay, D, Pears, J. Cardiovascular polypill. Current and evolving landscape for 
primary and secondary prevention, 
https://wellcome.ac.uk/sites/default/files/cardiovascular-polypill-feb17.pdf (2016, accessed 25 
July 2017) 
68. Beall RF, Schwalm J-DR, Huffman MD, et al. Could patents interfere with the development 
of a cardiovascular polypill? J Transl Med 2016; 14: 242. 
69. Wilkinson E. A look at the polypill story 10 years later. Interest in the polypill continues with 
an on-going study in the UK. Eur Heart J 2013; 34, 2019–2024 
70. Lopatowska P, Mlodawska E, Tomaszuk-Kazberuk A, et al. Adhering to the principles of 
clinical pharmacology - the correct fixed combinations of antihypertensive drugs. Expert Rev 
Clin Pharmacol. 2018;11(2):165-170. 
71. Kolte D, Aronow WS, Banach M. Polypills for the prevention of Cardiovascular diseases. 
Expert Opin Investig Drugs. 2016;25(11):1255-1264. 
72. Piepoli MF, Hoes AW, Agewall S, et al; ESC Scientific Document Group. 2016 European 
Guidelines on cardiovascular disease prevention in clinical practice: The Sixth Joint Task Force 
of the European Society of Cardiology and Other Societies on Cardiovascular Disease 
Prevention in Clinical Practice (constituted by representatives of 10 societies and by invited 
experts)Developed with the special contribution of the European Association for Cardiovascular 
Prevention & Rehabilitation (EACPR). Eur Heart J. 2016; 37(29):2315-2381. 
 
 
